Roberto Torres
About
Roberto Torres is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics.
According to data from OpenAlex, Roberto Torres has authored 20 papers receiving a total of 799 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Roberto Torres's work include Advanced Breast Cancer Therapies (9 papers), Cancer Treatment and Pharmacology (9 papers) and Estrogen and related hormone effects (7 papers). Roberto Torres is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Cancer Treatment and Pharmacology (9 papers) and Estrogen and related hormone effects (7 papers). Roberto Torres collaborates with scholars based in Chile, Brazil and Spain. Roberto Torres's co-authors include Guy Jérusalem, Didier Verhoeven, Kelly Pendergrass, Angelo Di Leo, Р. Ш. Хасанов, Luboš Petruželka, Sally Garnett, Igor Bondarenko, Miguel Martín and José Luiz Pedrini and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.
In The Last Decade
Roberto Torres
20 papers receiving 769 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Roberto Torres Chile | 8 | 570 | 532 | 302 | 280 | 127 | 20 | 799 | ||
| Sally Garnett United Kingdom | 9 | 614 1.1× | 544 1.0× | 340 1.1× | 269 1.0× | 147 1.2× | 12 | 847 | ||
| И А Смирнова Russia | 8 | 578 1.0× | 517 1.0× | 283 0.9× | 258 0.9× | 158 1.2× | 15 | 817 | ||
| SE Come United States | 8 | 429 0.8× | 249 0.5× | 355 1.2× | 288 1.0× | 103 0.8× | 19 | 652 | ||
| Dominique Spaëth France | 10 | 519 0.9× | 483 0.9× | 146 0.5× | 255 0.9× | 337 2.7× | 33 | 833 | ||
| William N. Harwin United States | 7 | 488 0.9× | 259 0.5× | 535 1.8× | 395 1.4× | 129 1.0× | 21 | 856 | ||
| Patrick Magill United Kingdom | 10 | 481 0.8× | 349 0.7× | 196 0.6× | 181 0.6× | 193 1.5× | 12 | 673 | ||
| Catherine Harper‐Wynne United Kingdom | 13 | 549 1.0× | 264 0.5× | 381 1.3× | 360 1.3× | 183 1.4× | 45 | 876 | ||
| E. Jane Macaskill United Kingdom | 12 | 329 0.6× | 130 0.2× | 232 0.8× | 244 0.9× | 133 1.0× | 18 | 533 | ||
| M. Azab United Kingdom | 6 | 547 1.0× | 228 0.4× | 390 1.3× | 303 1.1× | 156 1.2× | 7 | 845 | ||
| Roswitha Kammler Switzerland | 9 | 444 0.8× | 231 0.4× | 263 0.9× | 212 0.8× | 118 0.9× | 26 | 721 |
Countries citing papers authored by Roberto Torres
Since
Specialization
Citations
This map shows the geographic impact of Roberto Torres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Torres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Torres more than expected).
Fields of papers citing papers by Roberto Torres
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Roberto Torres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Torres. The network helps show where Roberto Torres may publish in the future.
Co-authorship network of co-authors of Roberto Torres
This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Torres. A scholar is included among the top collaborators of Roberto Torres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Torres. Roberto Torres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Torres, Roberto, et al.. (2025). Interaction of GPER-1 with the endocrine signaling axis in breast cancer. Frontiers in Endocrinology. 16. 1494411–1494411.
2.
Taylor, Clive R., Carlos H. Barrios, Manuel Ruíz-Borrego, et al.. (2024). Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial.. Journal of Clinical Oncology. 42(16_suppl). 516–516.
3.
Neciosup, Silvia P., Roberto Torres, César Sánchez, et al.. (2024). Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines. JCO Global Oncology. 10(10). e2200067–e2200067.
4.
Torres, Roberto, Dante Cáceres, Kuen Lee, et al.. (2021). Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients. Frontiers in Pharmacology. 12. 661443–661443.
5.
Leo, Angelo Di, Guy Jérusalem, Roberto Torres, et al.. (2018). First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. The Breast. 38. 144–149.
6.
Squiquera, Luis, Debra J. Taxman, Sarah A. Brendle, et al.. (2016). Ranpirnase Eradicates Human Papillomavirus in Cultured Cells and Heals Anogenital Warts in a Phase I Study. Antiviral Therapy. 22(3). 247–255.
7.
Ribi, Karin, Weixiu Luo, J. Bernhard, et al.. (2015). Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. Cancer Research. 75(9_Supplement). S3–9.
8.
Torres, Roberto, et al.. (2014). Communication Methods with Limited English Proficiency Research Participants to Acquire Informed Consent During Clinical Trials. SSRN Electronic Journal.
9.
Garnett, Sally, Miguel Martín, Guy Jérusalem, et al.. (2013). Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment. 138(1). 149–155.
10.
Leo, Angelo Di, Guy Jérusalem, Luboš Petruželka, et al.. (2013). Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. JNCI Journal of the National Cancer Institute. 106(1). djt337–djt337.
11.
Barrios, C.H., Aňa Lluch, Manuel Ruíz‐Borrego, et al.. (2013). Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC). Cancer Research. 73(24_Supplement). OT3–1.
12.
Lluch, Aňa, Manuel Ruíz‐Borrego, C.H. Barrios, et al.. (2012). 422 Final Safety Data From a Randomised Phase III Trial (CIBOMA/2004-01_GEICAM/2003-11) Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-negative Early Breast Cancer. a Study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Español De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer. 48. S169–S170.
13.
Leo, Angelo Di, Guy Jérusalem, Luboš Petruželka, et al.. (2012). Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. Cancer Research. 72(24_Supplement). S1–4.
14.
Lluch, Aňa, Henry Gómez, Manuel Ruíz‐Borrego, et al.. (2010). Abstract P5-10-15: First Safety Data from a Randomised Phase III (CIBOMA 2004- 01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy after Standard Chemotherapy for Triple-Negative Early Breast Cancer. Cancer Research. 70(24_Supplement). P5–10.
15.
Leo, Angelo Di, Guy Jérusalem, Luboš Petruželka, et al.. (2010). Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer. Journal of Clinical Oncology. 28(30). 4594–4600.
16.
Lluch, Aňa, C.H. Barrios, José Bines, et al.. (2009). 5150 CIBOMA/2004–01: a randomised phase III trial assessing adjuvant capecitabine (X) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC). European Journal of Cancer Supplements. 7(2). 305–305.
17.
Leo, Angelo Di, Guy Jérusalem, Luboš Petruželka, et al.. (2009). CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 25–25.
18.
Yazigi, R, et al.. (2006). Recurrent ovarian dysgerminoma after laparoscopy. International Journal of Gynecological Cancer. 16(S1). 397–399.
19.
Yazigi, R, et al.. (2006). Recurrent ovarian dysgerminoma after laparoscopy. International Journal of Gynecological Cancer. 16. 397–399.
20.
Torres, Roberto, et al.. (1996). [Laparoscopic cholecystectomy. Report of the first 1300 cases carried out by a multidisciplinary team].. PubMed. 16(2). 133–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sally Garnett Breakdown of academic impact, for papers by И А Смирнова Breakdown of academic impact, for papers by SE Come Breakdown of academic impact, for papers by Dominique Spaëth Breakdown of academic impact, for papers by William N. Harwin Breakdown of academic impact, for papers by Patrick Magill Breakdown of academic impact, for papers by Catherine Harper‐Wynne Breakdown of academic impact, for papers by E. Jane Macaskill Breakdown of academic impact, for papers by M. Azab Breakdown of academic impact, for papers by Roswitha Kammler